Sunshine Biopharma Inc. (SBFMW) shareholders
SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.03+0.00 (+2.00%)
Close on Oct 30, 2026Market cap $11.36MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
3
2 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bigger Michael | 1,610,000 | 9.47% | 13G (passive) | May 18, 2026 |
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (9.90%) | 1,588,266 | 9.90% | 13G (passive) | Oct 8, 2026 |
| BJI Financial Group | 909,900 | 6.00% | 13G (passive) | Oct 8, 2026 |
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%) | 505,653 | 9.99% | 13G (passive) | May 19, 2025 |
| Bigger Capital Fund L P Joint filing with Bigger Capital Fund GP, LLC (8.17%), Bigger Michael (8.17%) | 297,101 | 8.17% | 13G (passive) | Apr 2, 2025 |
| Intracoastal Capital LLC Joint filing with Mitchell P. Kopin (9.99%), Daniel B. Asher (9.99%) | 235,697 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SBFMW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 52,616 | – | $2.00K | New | 0.00% |
| UBS Group AG | 11,879 | – | $546 | −12,000 | 0.00% |
| Clear Street Group Inc. | 449 | – | $27 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 3 | 0M | 2 / 0 | 1 / 0 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0 / 1 | 0 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0 / 0 | 1 / 2 | 0M | 0M |
| Q3 2025 | 3 | 0M | 1 / 0 | 2 / 0 | 0M | 0M |
| Q2 2025 | 3 | 0M | 0 / 0 | 2 / 0 | 0M | 0M |
| Q1 2025 | 3 | 0M | 1 / 1 | 1 / 0 | 0M | 0M |
| Q4 2024 | 2 | 0M | 0 / 0 | 2 / 0 | 0M | 0M |
| Q3 2024 | 2 | 0M | 0 / 0 | 2 / 1 | 0M | 0M |
| Q2 2024 | 3 | 0M | 0 / 2 | 0 / 0 | 0M | 0M |
| Q1 2024 | 3 | 0M | 0 / 3 | 0 / 1 | 0M | 0M |
| Q4 2023 | 4 | 0M | 0 / 1 | 3 / 0 | 0M | 0M |
| Q3 2023 | 4 | 0M | 0 / 1 | 3 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Michel Roy | Chief Commercial Officer | 1 | Jan 21, 2025 |
| David Natan | Director | 68,300 | Aug 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David Natan Director | Aug 7, 2026 | Award | +58,300 | – | – | 68,300 |
| David Natan Director | Apr 14, 2026 | Award | +100,000 | – | – | 100,000 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Mar 4, 2024 | Buy | +100,000 | $0.10 | $10.00K | 130,000 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Feb 8, 2024 | Buy | +20,000 | $0.10 | $2.00K | 30,000 |
| Camille Sebaaly CFO/Secretary | Nov 30, 2022 | Buy | +30,000 | $0.76 | $22.80K | 174,465 |
| Camille Sebaaly CFO/Secretary | Jun 3, 2022 | Buy | +25,000 | $1.22 | $30.50K | 144,465 |
| Steve N. Slilaty Chief Executive Officer, Director | Feb 18, 2022 | Returned to company | −990,000 | $0.10 | $99.00K | 10,000 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Jan 6, 2021 | Award | +20,000,000 | – | – | 23,342,500 |
| Steve N. Slilaty Chief Executive Officer, Director | Jan 6, 2021 | Award | +20,000,000 | – | – | 23,343,461 |
| Camille Sebaaly CFO/Secretary, Director | Jan 6, 2021 | Award | +20,000,000 | – | – | 23,893,086 |
| Steve N. Slilaty Chief Executive Officer, Director | Jun 17, 2020 | Award | +500,000 | $0.10 | $50.00K | 1,000,000 |
| Camille Sebaaly CFO/Secretary, Director | Dec 31, 2019 | Award | −323,673 | – | – | 0 |
| Steve N. Slilaty Chief Executive Officer, Director | Dec 31, 2019 | Other | +323,673 | – | – | 861,209 |
| Camille Sebaaly CFO/Secretary, Director | Dec 19, 2019 | Award | +1,300,000 | – | – | 3,893,086 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Dec 19, 2019 | Award | +1,300,000 | – | – | 3,342,500 |
| Steve N. Slilaty Chief Executive Officer, Director | Dec 19, 2019 | Award | +1,300,000 | – | – | 3,343,461 |
| Camille Sebaaly CFO/Secretary, Director | Oct 20, 2019 | Award | +1,100,000 | – | – | 2,593,086 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Oct 20, 2019 | Award | +1,100,000 | – | – | 2,042,500 |
| Steve N. Slilaty Chief Executive Officer, Director | Oct 20, 2019 | Award | +1,100,000 | – | – | 2,043,461 |
| Camille Sebaaly CFO/Secretary, Director | Sep 11, 2019 | Award | +550,000 | – | – | 1,493,086 |
| Camille Sebaaly Secretary, Director, 10% owner | Sep 11, 2019 | Award | +11,000,000 | – | – | 29,861,719 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Sep 2, 2019 | Award | +13,000,000 | – | – | 18,850,000 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Sep 2, 2019 | Award | +13,000,000 | – | – | 18,869,219 |
| Camille Sebaaly Secretary, Director, 10% owner | Sep 2, 2019 | Award | +13,000,000 | – | – | 18,861,719 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Aug 27, 2018 | Award | +38,000,000 | – | – | 117,000,000 |
| Steve N. Slilaty Chief Executive Officer, Director | Aug 27, 2018 | Award | +38,000,000 | – | – | 117,384,373 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Aug 27, 2018 | Award | +38,000,000 | – | – | 118,467,000 |
| Camille Sebaaly Secretary, Director | Aug 27, 2018 | Award | +38,000,000 | – | – | 117,234,373 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Jun 20, 2018 | Award | +27,000,000 | – | – | 79,000,000 |
| Steve N. Slilaty Chief Executive Officer, Director | Jun 20, 2018 | Award | +27,000,000 | – | – | 79,384,373 |
| Camille Sebaaly Secretary, Director | Jun 20, 2018 | Award | +27,000,000 | – | – | 79,234,373 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Jun 20, 2018 | Award | +27,000,000 | – | – | 80,467,000 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Apr 22, 2018 | Award | +12,000,000 | – | – | 12,000,000 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Jul 20, 2017 | Award | +14,000,000 | – | – | 52,000,000 |
| Steve N. Slilaty Chief Executive Officer, Director | Jul 20, 2017 | Award | +14,000,000 | – | – | 52,384,373 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Jul 20, 2017 | Award | +14,000,000 | – | – | 53,467,000 |
| Camille Sebaaly Secretary, Director | Jul 20, 2017 | Award | +14,000,000 | – | – | 52,234,373 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Dec 6, 2016 | Award | +28,000,000 | – | – | 38,000,000 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Dec 6, 2016 | Award | +26,000,000 | – | – | 39,467,000 |
| Camille Sebaaly CFO and Secretary, Director | Dec 6, 2016 | Award | +26,000,000 | – | – | 38,234,373 |
| Steve N. Slilaty Chief Executive Officer, Director | Dec 6, 2016 | Award | +26,000,000 | – | – | 38,384,373 |
| Camille Sebaaly CFO and Secretary, Director, 10% owner | Oct 10, 2016 | Other | +129,468,927 | – | – | 129,468,927 |
| Corp Advanomics 10% owner | Oct 10, 2016 | Other | −136,861,968 | – | – | 215,014,224 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Oct 10, 2016 | Other | −136,861,968 | – | – | 215,014,224 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Jul 8, 2016 | Other | +321,305,416 | – | – | 351,876,192 |
| Steve N. Slilaty Chief Executive Officer, Director | Apr 22, 2016 | Award | +12,000,000 | $0.01 | $120.00K | 12,384,373 |
| Camille Sebaaly CFO and Secretary, Director | Apr 22, 2016 | Award | +12,000,000 | $0.01 | $120.00K | 12,234,373 |
| Abderrazzak Merzouki Chief Operating Officer, Director | Apr 22, 2016 | Award | +12,000,000 | $0.01 | $120.00K | 13,467,000 |
| Steve N. Slilaty Chief Executive Officer, Director | Apr 12, 2016 | Buy | +253,082 | $0.20 | $50.62K | 30,570,776 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | May 27, 2015 | Buy | +500,000 | $0.10 | $50.00K | 500,000 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Jan 9, 2015 | Other | +150,000 | $0.02 | $3.00K | 384,373 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Jan 9, 2015 | Other | −1,200,000 | $0.02 | $24.00K | 30,317,694 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Sep 4, 2012 | Other | −2,591,500 | $0.05 | $129.58K | 31,517,694 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Sep 4, 2012 | Sale | −2,591,500 | $0.05 | $129.58K | 31,517,694 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Dec 21, 2011 | Conversion | +17,000,000 | – | – | 34,109,194 |
| Steve N. Slilaty Chief Executive Officer, Director, 10% owner | Dec 21, 2011 | Conversion | +17,000,000 | – | – | 34,109,194 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
0.0%
From 0M shares
Short volume, 20 days
18.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sunshine Biopharma's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.